BiotechTube

Amifostine every-other-day regimen + Amifostine everyday regimen

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Neoplasms

Conditions

Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases, Mucositis

Trial Timeline

Jan 1, 2013 → Dec 1, 2019

NCT ID
NCT01762514

About Amifostine every-other-day regimen + Amifostine everyday regimen

Amifostine every-other-day regimen + Amifostine everyday regimen is a phase 2 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Neoplasms. The current trial status is unknown. This product is registered under clinical trial identifier NCT01762514. Target conditions include Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01762514Phase 2UNKNOWN

Competing Products

20 competing products in Nasopharyngeal Neoplasms

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
25
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
52
CisplatinSun PharmaceuticalPhase 3
77
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
77
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
77
CapecitabineSun PharmaceuticalPhase 3
77
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
77
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
77
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
77
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
52
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
77
Pemetrexed (Alimta)Eli LillyPhase 2
52
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
77
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
33
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
33
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
33
FamitinibJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
SHR-1210Jiangsu Hengrui MedicinePhase 2
52
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
41

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85